# Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial

> **NCT01260961** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 132 (estimated)

## Conditions studied

- Autism

## Interventions

- **DIETARY_SUPPLEMENT:** Placebo
- **DIETARY_SUPPLEMENT:** Docosahexanoic Acid

## Key facts

- **NCT ID:** NCT01260961
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-11
- **Primary completion:** 2015-07
- **Final completion:** 2025-12-01
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01260961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01260961, "Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01260961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*